Spirapril

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Spirapril
Spirapril structure.svg
Systematic (IUPAC) name
(8S)-7-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid
Clinical data
Trade names Renormax
AHFS/Drugs.com International Drug Names
Pregnancy
category
  • D
Routes of
administration
Oral
Legal status
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Bioavailability 50%
Metabolism converted to spiraprilat
Biological half-life 30 to 35 hours
Excretion Hepatic and renal
Identifiers
CAS Number 83647-97-6 YesY
ATC code C09AA11 (WHO)
PubChem CID 5311447
IUPHAR/BPS 6575
DrugBank DB01348 N
ChemSpider 4470933 YesY
UNII 96U2K78I3V YesY
KEGG D08529 YesY
ChEMBL CHEMBL431 YesY
Chemical data
Formula C22H30N2O5S2
Molar mass 466.616 g/mol
 NYesY (what is this?)  (verify)

Spirapril hydrochloride (Renormax) is an ACE inhibitor antihypertensive drug used to treat hypertension. It belongs to dicarboxy group of ACE inhibitors.[citation needed]

Spiraprilat — the active metabolite

Like many ACE inhibitors, this prodrug is converted to the active metabolite spiraprilat following oral administration. Unlike other members of the group, it is eliminated both by renal and hepatic routes, which may allow for greater use in patients with renal impairment.[1] However, data on its effect upon the renal function are conflicting.[2]

References[edit]

  1. ^ Shohat J, Wittenberg C, Erman A, Rosenfeld J, Boner G (1999). "Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension.". Scand J Urol Nephrol. 33 (1): 57–62. doi:10.1080/003655999750016294. PMID 10100366. 
  2. ^ Noble S, Sorkin E (1995). "Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.". Drugs. 49 (5): 750–66. doi:10.2165/00003495-199549050-00008. PMID 7601014.